Cardinal Health, APhA announce winners of annual GenerationRx Awards
DUBLIN, Ohio — The Cardinal Health Foundation and the American Pharmacists Association recently recognized pharmacists for their efforts in prescription medication misuse prevention.
During the APhA 2015 Annual Meeting and Exposition in San Diego, the Cardinal Health Foundation and APhA awarded the fifth annual American Pharmacists Association – Academy of Student Pharmacists (APhA-ASP) GenerationRx Awards, which recognize use of the GenerationRx toolkit, a communications package including talking points, presentation materials and tips to enable users to raise awareness of prescription drug misuse in their communities.
The organizations also awarded the fourth annual APhA GenerationRx Award of Excellence, an award recognizing one pharmacist for his or her outstanding efforts in prescription medication misuse prevention.
The APhA-ASP GenerationRx award is part of a national competition among APhA-ASP chapters. This past year, student pharmacists from 82 chapters conducted more than 800 GenerationRx presentations and educated more than 134,000 children, teens, college students and adults. More than 12.7 million people were reached via public relations outreach.
The 2015 APhA-ASP GenerationRx national and regional awards were presented during the APhA-ASP Opening General Session. The chapters honored in this year's competition were:
- National Award: East Tennessee State University Bill Gatton College of Pharmacy
- National 1st Runner-Up Award: University of Florida College of Pharmacy
- National 2nd Runner-Up Award: The University of New Mexico College of Pharmacy
- Region 1 Award: MCPHS University – Boston
- Region 2 Award: University of Pittsburgh School of Pharmacy
- Region 3 Award: The University of Tennessee Health Science Center College of Pharmacy
- Region 4 Award: Southern Illinois University Edwardsville School of Pharmacy
- Region 5 Award: Drake University College of Pharmacy and Health Sciences
- Region 6 Award: University of Arkansas for Medical Sciences College of Pharmacy
- Region 7 Award: Idaho State University College of Pharmacy
- Region 8 Award: University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
The 2015 recipient of the APhA GenerationRx Award of Excellence is Nathan Painter of La Jolla, California. Painter was selected in recognition of his commitment to community partnerships and interprofessional collaboration in providing substance misuse education. He is an Associate Clinical Professor at the University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, where he manages a pharmacist-run clinic for patients with chronic diseases. Painter serves as the faculty advisor for UCSD's APhA – Academy of Student Pharmacists (APhA-ASP) GenerationRx activities and created a prescription drug misuse elective course. He is an active member of the San Diego County Prescription Drug Abuse Task Force and has collaborated on an interprofessional team to evaluate the state's Prescription Drug Monitoring Program.
The awards mark a continuation of the APhA and Cardinal Health Foundation partnership to prevent the misuse of prescription medications. The organizations work together to provide a comprehensive education program to aid pharmacists and student pharmacists in educating their communities about the dangers of prescription drug misuse.
With more than 15 million people aged 12 or older using prescription drugs non-medically annually, prevention education is key to reversing the trend of misuse.
Generics company based in a small Minnesota town drawing interest from Wall Street
BAUDETTE, Minn. – ANI Pharmaceuticals is carving out a name for itself as a niche generic player here, according to a report published Monday by the MinnPost.
IMS: Americans filled a record 4.3 billion prescriptions in 2014
- Spending on medicines. Spending reached $373.9 billion in 2014, up 13.1%, the highest level since 2001 when growth was 17%. In addition to the lower impact from patent expiries and the record spending on new brands, price increases for protected brands also increased spending in 2014 by $26.3 billion, contributing 8.2% to total market growth on an invoice price basis. Estimated net price growth was substantially lower, as rising off-invoice discounts and rebates offset incremental price growth and reduced the net price growth contribution to 3.1%. Spending on specialty medicines increased $54 billion over the past five years, contributing 73% of overall medicine spending growth in that period. The biggest driver of specialty spending growth was the more than 161,000 patients who started treatment for hepatitis C in 2014, more than four times the previous peak as spending on widely adopted new treatments totaled $12.3 billion;
- Changes in the demand and payment for medicines. In the first full year of enrollment for expanded Medicaid and exchanges under the ACA, patients with Medicaid in states that expanded eligibility filled 25.4% more prescriptions than in the prior year, compared with 2.8% more in non-expansion states. Newly covered patients in Health Insurance Exchanges had slightly lower levels of increase in medicine use, and 70% of them were commercially insured in the prior year. Patients with employer-based insurance filled fewer prescriptions in 2014 due in part to the impact of rising co-pays and deductibles. High out-of-pocket costs can be mitigated with various forms of co-pay assistance, including coupons and vouchers. For example, as many as half of all branded prescriptions in newer diabetes treatments are now being supported in this way, compared with 8% of brands in all therapy areas. Overall, healthcare services demand shifted last year as patients had 3% fewer office visits and 1.7% fewer hospital admissions – but filled 2.1% more prescriptions; and
- Transformations in disease treatment. The drug R&D pipeline has shifted to specialty medicines over the past decade, with 42% of the late-stage pipeline now specialty – up from 33% 10 years ago. As many as 10 therapies were launched in 2014 with “Breakthrough Therapy” status as designated by the FDA under the 2012 FDA Safety and Innovation Act. Last year saw the largest number of orphan drugs launched in a single year, bringing the total number of treatments with orphan designation to 230. Cancer remains the most common orphan drug category, and nine “ultra-orphan” drugs – for populations fewer than 10,000 – became available last year. Among the most anticipated innovations are biosimilars – generic versions of biologic drugs – which began being filed for FDA review in 2014 with approvals already underway this year.